Advertisement

Topics

Complex Products At US FDA: Adamis' Epi-Pen Alternative OKed; Sandoz Advair ANDA Accepted

21:46 EDT 18 Jun 2017 | Elsevier Business Intelligence

The latest regulatory news on new versions of complex products and delivery systems from our FDA Performance Tracker. &#...

Original Article: Complex Products At US FDA: Adamis' Epi-Pen Alternative OKed; Sandoz Advair ANDA Accepted

NEXT ARTICLE

More From BioPortfolio on "Complex Products At US FDA: Adamis' Epi-Pen Alternative OKed; Sandoz Advair ANDA Accepted"

Advertisement
Quick Search
Advertisement
Advertisement